Talis Biomedical Corp expected to post a loss of $1.40 a share - Earnings Preview

Talis Biomedical

12/11/2021 22:24

* Talis Biomedical Corp  TLIS.OQ   TLIS.O  is expected to report
results on November 15.
* The Menlo Park, California-based company is expected to report
revenue of $1.46 million, according to the mean estimate from 3
analysts, based on Refinitiv data.  
​* Refinitiv's mean analyst estimate for Talis Biomedical Corp
is for a loss of $1.40 per share. 
* The current average analyst rating on the shares is "hold" and
the breakdown of recommendations is no "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Talis
Biomedical Corp is $7​, about 23% above​ its last closing price
of $5.39. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2021  -0.91       -0.91      -2.51     Missed  -175.1
 Mar. 31 2021  -0.75       -0.75      -4.61     Missed  -514.7
 Dec. 31 2020  -0.78       -0.78      -20.84    Missed  -2,554
                                                        .8​
 ​​                                                     
                                                        ​
 This summary was machine generated November 12 at 22:24 GMT. 
All figures in US dollars  unless otherwise stated